Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Completed · Phase 2
Conditions studied: Melanoma, Skin Neoplasms
In brief
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Key facts
- Study ID
- NCT00094107
- Run by
- Pfizer
- People needed
- 32
- Starts
- 2004-12-01
- Expected to finish
- 2008-04-01
- Last updated by the study team
- 2012-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically documented melanoma with metastases
- No more than 1 prior systemic therapy for metastatic disease (prior adjuvant therapy with interferon does not count as prior therapy for metastatic disease)
You may not qualify if…
- History of hemoptysis (coughing up of blood)
- Brain metastases
Where it is running
- Pfizer Investigational Site — Orange, California, United States
- Pfizer Investigational Site — Miami Beach, Florida, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Clairton, Pennsylvania, United States
- Pfizer Investigational Site — Greensburg, Pennsylvania, United States
- Pfizer Investigational Site — Johnstown, Pennsylvania, United States
- Pfizer Investigational Site — Pittsburgh, Pennsylvania, United States
- Pfizer Investigational Site — Pittsburgh, Pennsylvania, United States
- Pfizer Investigational Site — Wexford, Pennsylvania, United States
- Pfizer Investigational Site — Paris, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.